Saudi Arabia Center Advances Radiotherapy Technology with Nation's First Image Guided Cancer Treatment System from Elekta
-- King Abdulaziz University Hospital's Elekta Synergy boosts treatment speed for patient comfort, integrates imaging for patient safety
JEDDAH, Saudi Arabia, Jan. 9, 2013 /PRNewswire/ -- In part to address the 12,000 new cancer cases annually in Saudi Arabia – many of them diagnosed at an advanced stage – King Abdulaziz University Hospital is the first center nationally to acquire image guided treatment technology from Elekta. The 700-bed hospital launched a new era of advanced radiotherapy with the first clinical treatments on its Elekta Synergy® system in February 2012, offering patients with difficult cases sophisticated Image Guided Radiation therapy (IGRT) and Volumetric Modulated Arc Therapy (VMAT) for added precision and speed. The hospital also acquired Elekta treatment planning systems in May 2012.
"Managing the planning and treatment of late stage cancers is challenging," says Prof. Yasir Bahadur, M.D., Chairman of the Department of Radiology, under which the Department of Radiation Oncology operates. "We needed user-friendly technology that would allow us to accurately cover the target and protect normal tissues, while treating our patients in a comfortable and timely manner. We determined that Elekta Synergy met these needs from a technological standpoint."
The hospital had been operating two Siemens linear accelerators and added Elekta Synergy because of its advanced technology, such as kilovoltage [kV] cone beam CT [CBCT] and VMAT.
"While our whole radiotherapy practice has been image guided, the kV 3D volumetric imaging of Elekta Synergy enables us to accurately deliver complex treatment plans. The excellent quality of the kV treatment verification images – versus the megavoltage [MV] images the other linacs produce – allows a clear visualization of soft tissue structures without the need for implanted surrogate markers."
With Elekta Synergy, King Abdulaziz University Hospital has, for the first time, used VMAT in select cases, resulting in dramatic decreases in beam delivery time compared to conventional techniques.
"The beam delivery time for VMAT is about five minutes, compared to nine minutes for dynamic Intensity Modulated Radiation Therapy [IMRT] and 20 minutes for step-and-shoot IMRT," Prof. Bahadur notes. "In addition, we have found that delivery of IMRT is faster on Synergy versus our other systems.
"With Synergy," he continues, "we can easily treat 20 patients daily using either VMAT or dynamic IMRT, with daily CBCT, during eight working hours, which we were unable to do before. Now we can treat more patients and this has shortened our waiting list."
In addition to Synergy, King Abdulaziz University Hospital also acquired Elekta's XiO® and Monaco® treatment planning systems, and began using them clinically in May 2012.
"We like the accuracy of the dose calculation algorithms and high speed calculation of both treatment planning systems," Prof. Bahadur observes. "In Monaco, we appreciate the biological modeling feature and the Sensitivity Analysis tool that guide the planner through the plan optimization process."
As the hospital anticipates launching its new stereotactic radiation therapy (SRT) service in February 2013, Prof. Bahadur looks forward to the same level of Elekta support his team received in implementing advanced radiotherapy with Elekta Synergy.
"We have been impressed by the outstanding standard of training activities provided by Elekta to our staff," he remarks. "The professionalism of the application specialists, in addition to their kindness and continuous support are highly appreciated by the entire team. After nearly one year of using Elekta Synergy in our department, we are confident and satisfied with the system, and are very optimistic that with the launch of the SRT service, we will have another opportunity to strengthen our collaboration and partnership."
In July 2010, King Abdulaziz University Hospital introduced Elekta's MOSAIQ® Oncology Information System as an upgrade of its LANTIS record & verify system, and recently upgraded MOSAIQ to version 2.4.
"We find MOSAIQ very user-friendly and it integrated seamlessly with our Siemens linacs," Prof. Bahadur says.
For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46-702-100-451, email: email@example.com
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1-770-670-2447, email: firstname.lastname@example.org
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
Mer från detta företag
Okan University Hospital to Treat Cancer with Elekta Radiation Therapy Equipment
14 Apr, 2016, 15:00 CET
Dutch Medical Center Begins Radiosurgery Treatments with Elekta's Leksell Gamma Knife Icon
15 Mar, 2016, 07:00 CET
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till email@example.com eller ring oss på +46 (0)739 44 89 87 eller +46 (0)739 44 36 18
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)739 44 89 87 eller +46 (0)739 44 36 18